{"entity":{"id":"flonoltinib","kind":"drug","name":"Flonoltinib","aka":[],"tldr":"Flonoltinib is an oral kinase inhibitor from Chengdu Zenitar Biomedical Technology Co., Ltd, in registered phase 2 trials for myeloproliferative neoplasms.","summary":"Flonoltinib is listed on ClinicalTrials.gov as an intervention in 3 registered phase 2 trials sponsored by Chengdu Zenitar Biomedical Technology Co., Ltd, in myeloproliferative neoplasms. A kinase inhibitor: the name stem -tinib marks a small molecule that blocks a tyrosine kinase driving tumour growth. The registry record does not state which kinase unless named in the trial entries below. OnCo records the agent from the registry alone; approvals, results and the sponsor's own description will follow as they are published.","status":"phase-2","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov: trials of Flonoltinib","url":"https://clinicaltrials.gov/search?intr=Flonoltinib"}],"tags":["pipeline","ctgov-ingest","registry-only"],"related":[],"cancers":["myeloproliferative-neoplasms"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["nct07232290","nct07232290","nct07232290"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2, registry-only)","editedOn":"2026-09-16"},"modality":"Oral kinase inhibitor","mechanism":"A kinase inhibitor: the name stem -tinib marks a small molecule that blocks a tyrosine kinase driving tumour growth. The registry record does not state which kinase unless named in the trial entries below.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/flonoltinib/","neighbours":{"cancer":[{"id":"myeloproliferative-neoplasms","kind":"cancer","name":"Myeloproliferative neoplasms (PV, ET, myelofibrosis)","route":"/cancers/myeloproliferative-neoplasms/"}],"trial":[{"id":"nct07232290","kind":"trial","name":"Phase IIa Study of Flonoltinib Maleate Tablets in the Treatment of Patients With Polycythemia Vera","route":"/trials/nct07232290/"}]}}